Navigation Links
Roche Extends Tender Offer for Ventana
Date:1/16/2008

NG OTHER THINGS, STRATEGY, GOALS, PLANS OR INTENTIONS. VARIOUS FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY IN THE FUTURE FROM THOSE REFLECTED IN FORWARD-LOOKING STATEMENTS CONTAINED IN THIS DOCUMENT, AMONG OTHERS: (1) PRICING AND PRODUCT INITIATIVES OF COMPETITORS; (2) LEGISLATIVE AND REGULATORY DEVELOPMENTS AND ECONOMIC CONDITIONS; (3) DELAY OR INABILITY IN OBTAINING REGULATORY APPROVALS OR BRINGING PRODUCTS TO MARKET; (4) FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND GENERAL FINANCIAL MARKET CONDITIONS; (5) UNCERTAINTIES IN THE DISCOVERY, DEVELOPMENT OR MARKETING OF NEW PRODUCTS OR NEW USES OF EXISTING PRODUCTS, INCLUDING WITHOUT LIMITATION NEGATIVE RESULTS OF CLINICAL TRIALS OR RESEARCH PROJECTS, UNEXPECTED SIDE-EFFECTS OF PIPELINE OR MARKETED PRODUCTS; (6) INCREASED GOVERNMENT PRICING PRESSURES; (7) INTERRUPTIONS IN PRODUCTION; (8) LOSS OF OR INABILITY TO OBTAIN ADEQUATE PROTECTION FOR INTELLECTUAL PROPERTY RIGHTS; (9) LITIGATION; (10) LOSS OF KEY EXECUTIVES OR OTHER EMPLOYEES; AND (11) ADVERSE PUBLICITY AND NEWS COVERAGE. THE STATEMENT REGARDING EARNINGS PER SHARE GROWTH IS NOT A PROFIT FORECAST AND SHOULD NOT BE INTERPRETED TO MEAN THAT ROCHE'S EARNINGS OR EARNINGS PER SHARE FOR ANY CURRENT OR FUTURE PERIOD WILL NECESSARILY MATCH OR EXCEED THE HISTORICAL PUBLISHED EARNINGS OR EARNINGS PER SHARE OF ROCHE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL VENTANA'S COMMON STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) FILED BY ROCHE WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") ON JUNE 27, 2007. THESE MATERIALS, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER, THAT SHOULD BE READ CAREFULLY BE
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
2. Roche Files IND for Second Genmab Antibody
3. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
4. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
5. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
6. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
7. Kosan to Reacquire Epothilone Program From Roche
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
11. Med Ad News Honors Roche as Company of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
(Date:9/15/2014)... , Sept. 15, 2014 The chemistry, taste, ... climate, says a new article published by the nonprofit American ... PhD, on climate change and its effects on the phytochemical ... an extensive study conducted by Dr. Ahmed in the ... and has implications for the future of medicinal ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated ... biomaterials including bioimplants processed from human amniotic membrane, ... offering to sell common stock and warrants has ... of the offering on October 30, 2010, through ...
... 5, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... engaged Congressman Curt Weldon to assist in supporting ... at a press conference in New York City ... Congressman Weldon will source, evaluate, and ...
... NEW YORK, July 4, 2011 Reportlinker.com ... is available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0567594/Stem-Cell-Technologies-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... market develop this decade? Our new report ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 2Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 3Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America 4Stem Cell Technologies: World Market Outlook 2011-2021 2Stem Cell Technologies: World Market Outlook 2011-2021 3Stem Cell Technologies: World Market Outlook 2011-2021 4Stem Cell Technologies: World Market Outlook 2011-2021 5Stem Cell Technologies: World Market Outlook 2011-2021 6Stem Cell Technologies: World Market Outlook 2011-2021 7Stem Cell Technologies: World Market Outlook 2011-2021 8Stem Cell Technologies: World Market Outlook 2011-2021 9Stem Cell Technologies: World Market Outlook 2011-2021 10Stem Cell Technologies: World Market Outlook 2011-2021 11Stem Cell Technologies: World Market Outlook 2011-2021 12
(Date:9/15/2014)... fears that reef biodiversity may not provide the level ... , In an international study published today, Professor David ... Reef Studies (Coral CoE) says we need to identify ... , In coral reefs, just as in any modern-day ... safe and functioning. , Professor Bellwood says, in ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Conditions on Earth for the first 500 million years ... the present day, complete with oceans, continents and active ... geologic eon, called the Hadean, has gained substantial new ... that formed more than 4 billion years ago with ... as a possible geological analog for early Earth. , ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... The MitoPT kit is used in conjunction with ... culture and induce apoptosis according to your existing ... as a negative control). Once you have induced ... solution to each population and incubate the cells ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: